Longboard Pharmaceuticals announced that the FDA has granted Breakthrough Therapy designation for its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies, or DEEs, for patients two years of age or older.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LBPH:
- Longboard Pharmaceuticals Advances with Promising Seizure Treatment Study
- Longboard announces interim results from OLE of bexicaserin study for DEEs
- Longboard Pharmaceuticals price target raised to $34 from $32 at Wedbush
- Longboard Pharmaceuticals reports Q1 EPS (42c), consensus (49c)
- Starbucks downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls